CG Oncology (CGON) Cash from Investing Activities (2023 - 2026)

CG Oncology's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$334.8 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 79.28% year-over-year to -$334.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$393.9 million (down 118.72% YoY) and the FY2025 annual result came in at -$245.8 million, up 18.27% from the prior year.
• Cash from Investing Activities was -$334.8 million for Q1 2026 at CG Oncology, down from -$75.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $103.4 million in Q2 2023 and bottomed at -$334.8 million in Q1 2026.
• A 4-year average of -$77.1 million and a median of -$36.2 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 119.83% — and 2025, when it tumbled 792.39%.
• CG Oncology's Cash from Investing Activities stood at $15.5 million in 2023, then declined by 29.8% to $10.9 million in 2024, then tumbled by 792.39% to -$75.5 million in 2025, then tumbled by 343.47% to -$334.8 million in 2026.
• Business Quant data shows CGON's Cash from Investing Activities at -$334.8 million in Q1 2026, -$75.5 million in Q4 2025, and $15.0 million in Q3 2025.